Approved: _	February 6, 2009
	Date

MINUTES OF THE SENATE COMMERCE COMMITTEE

The Joint Committee of the House Eco Devo-Tourism and the Senate Commerce Committees was called to order by Chairman Lana Gordon at 11:50 a.m. on January 28, 2009, in Room 748 at the Docking Building.

All members were present except:

Senator Jay Emler- excused Senator Susan Wagle- excused

Committee staff present:

Ms. Margaret Cianciarulo, Committee Assistant

Mr. Ken Wilke, Office of the Revisor of Statutes

Mr. Reed Holwegner, Kansas Legislative Research Department

Conferees appearing before the Committee:

Dr. Roy Jensen, Director, The Cancer Center

Mr. Gary Sherrer, Chairman, Midwest Cancer Institute

Others attending:

Presentation on the Cancer Institute Initiative Updates

Upon opening the meeting, the Chair thanked the Senate Commerce Committee for being able to attend as they had been in Senate session. She then introduced Dr. Roy Jensen, Director of The Cancer Center, offering the 2009 facts and figures in Kansas from the American Cancer Institute including

- Patients having to travel 200 to 700 miles to reach an NCI-designated Comprehensive Cancer Center.
- The cost of \$2.08 billion is the annual figure in medical expenses and lost productivity.
- Their vision and their mission.
- The process NCI's Roadmap which are six essential criteria (what NCI looks at).
- NCI designation differentiations and their results.

Dr. Jensen then introduced Mr. Gary Sherrer, Chairman, Midwest Cancer Institute, who continued the testimony from page 5 and 6 including:

- Listing some of the members of the Midwest Cancer Alliance located through the state such as Stormont-Vail, Via Christi, Goldband and Children's Mercy;
- Highlights of Phase I (2006 2008) which covered drug discovery, delivery and development and clinical research.

He concluded by saying the economic impact of this project would be the creation of 9,000 jobs and a billion dollars plus each year of economic impact.

Mr. Sherrer then referred back to Dr. Jensen who continued with the testimony covering the next steps:

- NCI designation Critical Success Factors and Phase II & Phase III (2009 2016).
- Extramural funding goals (NCI funding FY 05-07 & projection FY 11 & FY 16).
- The benefits (\$1 million in NIH funding = \$2.21 million in new state economic activity).

CONTINUATION SHEET

Minutes of the Joint Committee with the House Eco Devo-Tourism Committee and the Senate Commerce Committee at 11:50 .a.m. on January 28, 2009, in Room 748 at the Docking Building. Page 2

- And, their focus on the future.

A copy of their presentation is (Attachment 1) attached and incorporated into the Minutes as referenced.

The Chair thanked Dr. Jensen and Mr. Sherrer. He then asked for questions or comments from the Committees which came from Senators Faust-Goudeau, Lynn, and Wysong, Representatives Furtado and Gordon including:

- With respect to the NCI patients on clinical trials, will their care or other needs be coordinated with any of the hospitals throughout the state or will they have to go to a specific hospital in coordinated care and does the NCI designation encourage serving the indigent or uncompensated?
- Do you have any major competition from any other neighboring states with doing any other innovative research centers?
- Regarding the Salina Regional, is Via Christi taking care of them or is there talk to include them?
- Regarding KBA, what are they doing now and where are they headed?

Adjournment

As there was no more discussion, the Chair adjourned the meeting. The time was 12:50 p.m.

The next Commerce Committee meeting is scheduled for Thursday, January 29, 2009.



Comprehensive Cancer Research-to-Care Initiative

Senate Commerce Committee Add : January 28,2009

THE UNIVERSITY OF KANSAS CANCER CENTER

Roy Jensen, MD
Director, The University of Kansas
Cancer Center
January 28, 2009

In Kansas...

12,520 will be diagnosed in 2008

5,360 will die in 2008

Cancer mortality rate reductions in KS (-0.5%) are **one-fourth** the national trends (-2.1%)

\$2.08 billion annually in medical expenses and lost productivity

Cancer patients must travel 200 to 700 miles to reach an NCI-designated Comprehensive Cancer Center

Our Vision

Reduce the burden of cancer in Kansas and save lives.

Our Mission

Build a Comprehensive Cancer Center based on collaboration and innovation.

NCI's Roadmap – 6 Essential Criteria



NCI Designation Differentiators

Drug Discovery,
Delivery &
Development

Office of Therapeutics Discovery & Development

Clinical Trials Office Community-based Approach



Prevention & Control Research

Rural Primary Care Outreach Breast Cancer Prevention & Survivorship Centers


Results

More advanced cancer prevention, early detection, treatment, and survivorship

Midwest Cancer Alliance

- Launched Clinical Trials Network
- Launched Partners Advisory Board






Highlights: Phase I 2006-2008

- Drug Discovery, Delivery & Development
 - Launched Office of Therapeutics Discovery & Development led by Scott Weir, PharmD, PhD
 - » Institute for Advancing Medical Innovation Kauffman Grant
 - » Academic drug discovery, development, and delivery partner for Leukemia & Lymphoma Society
 - » Half of all projects in pipeline are cancer specific

Clinical Research

- » Initiated Phase I Nanotax clinical trial
- » Doubled number of patients enrolled on clinical trials in 2008
- » In 2008, MCA screened 4,256 people
 - 236 people were encouraged to follow-up with their physician because of an abnormal finding

NCI-designation Critical Success Factors




Phase II and III (2009-2016)


- Renovate and build state-of-the-art, well-equipped cancer research facilities.
- Attract 60 top-flight cancer scholars
- Expand # patients enrolled in clinical trials through the Midwest Cancer Alliance
- Achieve \$10-11 M in NCI funding by 2011 and \$15-20 M by 2016
- Apply for National Cancer Institute Cancer Center designation on September, 25, 2011
 - » Comprehensive Cancer Center designation in 2016

Extramural Funding Goals


NCI Funding FY 05-07 & Projection FY 11 & FY 16



\$1 million in NIH funding = \$2.21 million in new state economic activity



Investing in Cancer is a No Regret Initiative



A significant return on investment occurs with or without NCI designation